140 related articles for article (PubMed ID: 7738716)
1. Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer.
Lipponen PK
J Pathol; 1995 Feb; 175(2):203-10. PubMed ID: 7738716
[TBL] [Abstract][Full Text] [Related]
2. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
3. Expression of cathepsin D in transitional cell bladder tumours.
Lipponen PK
J Pathol; 1996 Jan; 178(1):59-64. PubMed ID: 8778318
[TBL] [Abstract][Full Text] [Related]
4. Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder: a study in Greek patients.
Gorgoulis VG; Barbatis C; Poulias I; Karameris AM
Mod Pathol; 1995 Sep; 8(7):758-64. PubMed ID: 8539234
[TBL] [Abstract][Full Text] [Related]
5. Expression of c-erbB-2 protein in normal and neoplastic urothelium: lack of adverse prognostic effect in human urinary bladder cancer.
Lee SE; Chow NH; Chi YC; Tzai TS; Yang WH; Lin SN
Anticancer Res; 1994; 14(3B):1317-24. PubMed ID: 7915094
[TBL] [Abstract][Full Text] [Related]
6. Expression of c-myc proteins in breast cancer as related to established prognostic factors and survival.
Pietiläinen T; Lipponen P; Aaltomaa S; Eskelinen M; Kosma VM; Syrjänen K
Anticancer Res; 1995; 15(3):959-64. PubMed ID: 7645986
[TBL] [Abstract][Full Text] [Related]
7. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer.
Lipponen HJ; Aaltomaa S; Syrjänen S; Syrjänen K
Anticancer Res; 1993; 13(4):1147-52. PubMed ID: 8102517
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis.
Lipponen PK; Aaltomaa S
J Pathol; 1994 Aug; 173(4):333-9. PubMed ID: 7965393
[TBL] [Abstract][Full Text] [Related]
9. Classic prognostic factors, flow cytometric data, nuclear morphometric variables and mitotic indexes as predictors in transitional cell bladder cancer.
Lipponen PK; Eskelinen MJ; Kiviranta J; Nordling S
Anticancer Res; 1991; 11(2):911-6. PubMed ID: 2064350
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications.
Popov Z; Gil-Diez-De-Medina S; Ravery V; Hoznek A; Bastuji-Garin S; Lefrere-Belda MA; Abbou CC; Chopin DK
Urol Oncol; 2004; 22(2):93-101. PubMed ID: 15082004
[TBL] [Abstract][Full Text] [Related]
11. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
12. Expression of p53 protein has no independent prognostic value in breast cancer.
Pietiläinen T; Lipponen P; Aaltomaa S; Eskelinen M; Kosma VM; Syrjänen K
J Pathol; 1995 Nov; 177(3):225-32. PubMed ID: 8551383
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome.
Krüger S; Weitsch G; Büttner H; Matthiensen A; Böhmer T; Marquardt T; Sayk F; Feller AC; Böhle A
Int J Oncol; 2002 Nov; 21(5):981-7. PubMed ID: 12370744
[TBL] [Abstract][Full Text] [Related]
14. Growth factors and oncogene products in transitional cell carcinoma.
Nakanishi K; Kawai T; Suzuki M; Torikata C
Mod Pathol; 1996 Mar; 9(3):292-7. PubMed ID: 8685230
[TBL] [Abstract][Full Text] [Related]
15. c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival.
Giatromanolaki A; Koukourakis MI; Sivridis E; Fountzilas G
Anticancer Res; 2000; 20(2A):997-1004. PubMed ID: 10810387
[TBL] [Abstract][Full Text] [Related]
16. Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations.
Volm M; Efferth T; Mattern J
Anticancer Res; 1992; 12(1):11-20. PubMed ID: 1348920
[TBL] [Abstract][Full Text] [Related]
17. Stereologically measured nuclear volume in comparison to two-dimensional nuclear morphometry, mitotic index and flow cytometry in predicting disease outcome in bladder cancer.
Lipponen PK
Anticancer Res; 1993; 13(2):529-32. PubMed ID: 8517668
[TBL] [Abstract][Full Text] [Related]
18. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up.
Lipponen P; Aaltoma S; Kosma VM; Ala-Opas M; Eskelinen M
J Pathol; 1998 Oct; 186(2):157-64. PubMed ID: 9924431
[TBL] [Abstract][Full Text] [Related]
19. c-erbB-2 (HER-2/neu) oncopeptide immunoreactivity in localized, high-grade transitional cell carcinoma of the bladder.
Swanson PE; Frierson HF; Wick MR
Mod Pathol; 1992 Sep; 5(5):531-6. PubMed ID: 1364264
[TBL] [Abstract][Full Text] [Related]
20. Relationship between AgNORs, MIB-1 and oncogene expression in male breast carcinoma and papillary superficial bladder neoplasm.
Pich A; Margaria E; Chiusa L; Bortolin P; Palestro G
Oncol Rep; 2003; 10(5):1329-35. PubMed ID: 12883702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
